Targeted anti-vascular therapies for ovarian cancer: Current evidence

British Journal of Cancer

Volumn 108, Issue 2, 2013, Pages 250-258

  Hall, M ^a   Gourley, C ^b   Mcneish, I ^c   Ledermann, J ^d   Gore, M ^e   Jayson, G ^f   Perren, T ^g   Rustin, G ^a   Kaye, S ^e  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f CHRISTIE HOSPITAL   (United Kingdom)

^g ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Anti angiogenesis; Metronomic chemotherapy; Ovary cancer; Tyrosine kinase inhibitors; Vascular disruptive agents; VEGF inhibitors

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; NINTEDANIB; PACLITAXEL; PAZOPANIB; TOPOTECAN; TREBANANIB; VADIMEZAN;

BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; DIGESTIVE SYSTEM PERFORATION; DRUG HALF LIFE; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; INTESTINE OBSTRUCTION; LOW DRUG DOSE; MAINTENANCE THERAPY; METRONOMIC DRUG ADMINISTRATION; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; REVIEW; RISK FACTOR; TRANSIENT ISCHEMIC ATTACK; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANGIOPOIETINS; ANGIOSTATINS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIBENZYLS; FEMALE; FIBROBLAST GROWTH FACTORS; FLAVONOIDS; HUMANS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; THROMBOSPONDINS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84873619713     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.541     Document Type: Review

References (63)

1. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR (2012) OCEANS: A randomised, doubleblinded, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab in patients with platinum sensitive recurrent epithelial ovarian, primary peritoneal or fallopian tube cancer. J Clin Oncol 30: 2039-2045.
2. Aghajanian C, Blank SV, Goff BA, Judson PL, Nycum LR, Sovak MA, Yi J, Hussain A (2012) An updated safety analysis of OCEANS, a randomised double-blinded, phase III trial of gemcitabine and carboplatin with bevacizumab or placebo followed by bevacizumab or placebo to disease progression in patients with platinum sensitive recurrent ovarian cancer. J Clin Onc 30(suppl): Abstr 5054.
3. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2(11): 1843-1849. (Pubitemid 26384151)
4. Biagi JJ, Oza AM, Chalchal HI, Grimshaw R, Ellard SL, Lee U, Hirte H, Sederias J, Ivy SP, Eisenhauer EA (2011) A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: An NCIC Clinical Trials Group Study. Ann Oncol 22(2): 335-340.
5. Bornstein P (1995) Diversity of function is inherent in matricellular proteins: An appraisal of thrombospondin 1. J Cell Biol 130(3): 503-506.
6. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study. J Clin Onc 25: 5165-5171. (Pubitemid 350237599)
7. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX (2011) The incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365: 2473-2483.
8. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25(33): 5180-5186. (Pubitemid 350232248)
9. Cassidy J, Saltz LB, Giantonio BJ, Kabbinavar FF, Hurwitz HI, Rohr UP (2010) Effect of bevacizumab in older patients with metastatic colorectal cancer: Pooled analysis of four randomized studies. J Cancer Res Clin Oncol 136: 737-743.
10. Chura JC, Van Iseghem K, Downs Jr LS, Carson LF, Judson PL (2007) Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynaecol Oncol 107(2): 326-330. (Pubitemid 47575735)
11. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A (2003) A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30: 117-124. (Pubitemid 37433402)
12. Cohn AL, Bekaii-Saab T, Bendell JC, Hurwitz H, Kozloff N, Roach H, Tezcan S, Feng A, Sing A, Grothey A (2010) Clinical outcomes in bevacizumab treated patients with metastatic colorectal cancer: Results from ARIES observational cohort study and confirmation of BRiTE data on BV beyond progression. J Clin Oncol 28(15s suppl): Abstr 3596.
13. Colombo. N (2011) Efficacy of trabectidin in platinum-sensitive relapsed ovarian cancer: New data from the randomised OVA-301 study. Int J Gyn Oncol 21: S12-S16.
14. Cortes J, Calvo V, Ramirez-Merino N, O'Shaughnessy J, Brufsky A, Robert N, Vidal M, Munoz E, Perez J, Dawood S, Saura C, Di Cosimo S, Gonzalez-Martin A, Bellet M, Silva OE, Miles D, Llombart A, Baselga J (2012) Adverse events associated with bevacizumab adddition to breast cancer chemotherapy: A meta- analysis. Annals of Onc 23: 1130-1137.
15. de Gramont A, de Gramont A, Chibaudel B, Bachet J-B, Larsen AK, Tournigand C, Louvet C, Andre T. for GERCOR (French Oncology Research Group) (2011) Targeted therapy in adjuvant treatment for stage III colon cancer. Semin Oncol 38(4): 521-532.
16. Diaz JP, Tew WP, Zivanovic O, Konner J, Sabbatini PJ, dos Santos LA, Abu-Rustum NR, Chi DS, Aghajanian C, Barakat RR (2010) Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma. Gynecol Oncol 116: 335-339.
17. Duska LR, Garrett L, Henretta M, Ferris JS, Lee L, Horowitz N (2010) When 'never-events' occur despite adherence to clinical guidelines: The case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. Gyn Oncol 116: 374-377.
18. Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15(3): 232-239.
19. Friedlander M, Hancock KC, Rischin D, Messing MJ, Stringer CA, Matthys GM, Ma B, Hodge JP, Lager JJ (2010) A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 119: 32-37.
20. Gaitskell K, Martinek I, Bryant A, Kehoe S, Nicum S, Morrison J (2011) Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev 9: CDD007930.
21. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder D, Morgan R, Chen H, Lenz HJ, Oza AM (2008) Phase II clinical trial of bevacizumab and lowdose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California,Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26: 76-82.
22. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB (2007) High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 25: 1539-1544. (Pubitemid 46733080)
23. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M (2008) Bevacizumab beyond first progression is assoiciated with prolonged overall survival in metastatic colorectal cancer: Results from a loarge observational cohort study (BRiTE). J Clin Onc 26: 5326-5334.
24. Hall M, Rustin G (2010) A retrospective review of low dose oral cyclophosphamide alone and in combination with tamoxifen and prophylactic warfarin in heavily pretreated ovarian cancer. Int J Gyn Cancer 20((suppl)): Abstr 467.
25. Han ES, Monk BJ (2007) What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 105: 3-6. (Pubitemid 46441477)
26. Hashimoto K, Man S, XüP, Cruz-Munoz W, Tang T, Kumar R, Kerbel RS (2010) Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther 9(4): 996-1006.
27. Hensley M (2011) Big costs for little gain in ovarian cancer. J Clin Onc 29: 1230-1232.
28. Horsman MR, Siemann DW (2006) Pathophysiologic effects of vasculartargeting agents and the implications for combination with conventional therapies. Cancer Res 66(24): 11520-11539. (Pubitemid 46094158)
29. Hurt JD, Richardson DLR, Seamon LG, Fowler JF, Copeland LJ, Cohn DE, Eisenhauer E, Salani R, O'Malley DM (2009) Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. Gynecol Oncol 115: 396-400.
30. Hurwitz HI, Salt LB, Van Cutsem E, Cassidy J, Wiedemann J, Sirzen F, Lyman GH, Rohr UP (2011) Venous thromboembolic events with chemotherapy plus bevacizumab: A pooled analysis of patients in randomised phase II and III studies. J Clin Onc 29(13): 1757-1764.
31. Jain RK (2005) Antiangiogenic therapy for cancer: Current and emerging concepts. Oncology (Williston Park) 19(4 Suppl 3): 7-16.
32. Javier Cortes MC, Delaloge S, Cortes-Funes H, Pierga J-Y, Pritchard K, Bollag DT, Miles DW (2012) Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. Eur J Cancer 48: 475-481.
33. Jayson GC, de Haas S, Delmar P, Miles DW, Shah MA, Van Cutsem E, Carmeliet P, Hegde P, Wild N, Scherer SJ (2011) Evaluation of plasma VEGFA as a pan-tumour biomarker for the treatment of patients with bevacizumab. ESMO/ECCO Sweden, 2011 Abstr 804.
34. Kabbinavar FF, Flynn PJ, Kozloff M, Ashby MA, Sing A, Barr CE, Grothey A (2012) Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: Results from a large treatment observational cohort study. Eur J Cancer 48: 1126-1132.
35. Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, Buck M, Chambers SK, Ghatage P, Pippitt Jr CH, Brown 3rd JV, Covens A, Nagarkar RV, Davy M, Leath 3rd CA, Nguyen H, Stepan DE, Weinreich DM, Tassoudji M, Sun YN, Vergote IB (2012) Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 30(4): 362-371.
36. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Iobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K. for the JGOG (2012) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial. J Clin Oncol 30(suppl): Abstr 5003.
37. Khorana AA, Dalal M, Lin J, Connolly GC (2012) Incidence and predictors of venous thomboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer; e-pub ahead of print 14 August 2012; doi:10.1002/cncr.27772.
38. Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D (2009) Intraperitoneal VEGF inhibition using bevacizumab: A potential approach for the symptomatic treatment of malignant ascites? Oncologist 14(12): 1242-1251.
39. Kristensen G, Perren T, Qian W, Pfisterer J, Ledermann JA, Joly F, Carey MS, Beale PJ, Cervantes A, Oza AM. for GCIG (2012) Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. J Clin Onc 30(suppl): Abstr 5006.
40. Le T, Hopkins L, Baines KA, Rambout L, Al Hayki M, Kee Fung MF (2006) Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer. Gynecol Oncol 102(1): 49-53. (Pubitemid 43851048)
41. Ledermann JA, Hackshaw A, Kaye S, Jayson G, Gabra H, McNeish I, Earl H, Perren T, Gore M, Persic M, Adams M, James L, Temple G, Merger M, Rustin G (2011) Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 29(28): 3798-3804.
42. Lortholary A, Largillier R, Weber B, Gladieff L, Alexandre J, Durando X, Slama B, Dauba J, Paraiso D, Pujade-Lauraine E. on behalf of GINECO group France (2011) Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: The CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO). Ann Oncol 23(2): 346-352.
43. Matei D, Sill MW, Lankes HA, DeGeest K, Bristow RE, Mutch D, Yamada SD, Cohn D, Calvert V, Farley J, Petricoin EF, Birrer MJ (2011) Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: A Gynecologic Oncology Group trial. J Clin Oncol 29(1): 69-75.
44. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenbilt A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT (2009) Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 27: 5601-5606.
45. McKeage MJ (2011) Clinical trials of vascular disrupting agents in advanced non-small-cell lung cancer. Lung Cancer 12(3): 143-147(3): 143-147.
46. Merritt WM, Nick AM, Carroll AR, LüC, Matsuo K, Dumble M, Jennings N, Zhang S, Lin YG, Spannuth WA, Kamat AA, Stine RL, Shahzad MMK, Coleman RL, Kumar R, Sood AK (2010) Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Camcer Ther 9(4): 985-995.
47. Miles D, Bridgewater J, Ellis P, Harrison M, Nathan P, Nicolson M, Raouf S, Wheatley D, Plummer C (2010) Using Bevacizumab to treat metastatic cancer: UK consensus guidelines. Br J Hosp Med 71(12): 670-677.
48. Miles D, Harbeck N, Escudier B, Hurwitz H, Saltz L, Van Cutsem E, Cassidy J, Mueller B, Sirzen F (2011) Disease course patterns after discontinuation of bevacizumab: Pooled analysis of randomized phase III trials. J Clin Oncol 29: 83-88.
49. Miller KD, Sweeney CJ, Sledge GW (2001) Redefining the target: Chemotherapeutics as antiangiogenics. J Clin Oncol 19(4): 1195-1206. (Pubitemid 32176298)
50. Nakayama G, Uehara K, Ishigure K, Yokoyama H, Ishiyama A, Eguchi T, Tsuboi K, Ohashi N, Fuji T, Sugimoto H, Kolke M, Fujiwara M, Abdo Y, Kodera Y (2012) The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancr: A multicentre, single-arm,phase II trial (CCOG-0801). Cancer Chemother Pharmacol 70(4): 575-581.
51. O'Malley DM, Richardson DL, Rheaume PS, Salani R, Eisenhauer EL, McCann GA, Fowler JM, Copeland LJ, Cohn DE, Backes FJ (2011) Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol 121(2): 269-272.
52. Okines A, Langley RE, Thompson LC, Stenning SP, Stevenson L, Falk S, Seymour M, Coxon FY, Middleton GW, Smith D, Evans L, Slater S, Waters JS, Ford D, Hall M, Iveson T, Petty RD, Plummer C, Allum W, Cunningham D. The National Cancer Research Institute (NCRI) Upper GI Cancers Clinical Studies Group (2011) Safety results from a randomised trial of preoperative epirubicin, cisplatin plus capecitabine with or without bevacizumab in patients with gastric or type II/III oesophagogastric junction adenocarcinoma. Ann Oncol; e-pub ahead of print 28 October 2012; doi:10.1093/annonc/mds533.
53. Pasquier E, Honore S, Pourroy B, Jordan MA, Lehmann M, Briand C, Braguer D (2005) Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 65(6): 2433-2440. (Pubitemid 40490155)
54. Pegram M, Liao J (2012) Trastuzumab treatment in multiple lines: Current data and future directions. Clin Breast Cancer 12(1): 10-18.
55. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, düBois A, Sehouli J, Kimmig R, Sta?hle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen AR, Plante M, Stark D, Qian W, Parmar MKB, Oza AM for the ICON7 Investigators.*(2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365: 2484-2496.
56. Pujane-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D. Ray-Coquard I on behalf of the ENGOT-GCIG investigators (2012) AURELIA: A randomised phase III trial evaluating bevacizumab combined with chemotherapy for platinumresistant recurrent ovarian cancer. J Clin Oncol 30(suppl): Abstr LBA5002.
57. Richardson DL, Backes FJ, Hurt JD, Seamon LG, Copeland LJ, Fowler JM, Cohn DE, O'Malley DM (2010) Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? Gynecol Oncol 118: 47-51.
58. Rustin GJ, Bradley C, Galbraith S, Stratford M, Loadman P, Waller S, Bellenger K, Gumbrell L, Folkes L, Halbert G. Phase I/II Trials Committee of Cancer Research UK (2003) 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: Phase I clinical and pharmacokinetic study. Br J Cancer 88(8): 1160-1167. (Pubitemid 36606327)
59. Sandler AB, Gray R, Perry M, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel -carboplatin alone or with bevacizumab for non-small-cell-lung cancer. N Engl J Med 355: 2542-2550. (Pubitemid 44917502)
60. Sfakianos GP, Numnum TM, Halverson CB, Panjeti D, Kendrick IV JE, Straughn Jr JM (2009) The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: A retrospective cohort study. Gynecol Oncol 114: 424-426.
61. Tillmans TD, Reed ME, Privett MC, Johns AL, Walker MS, Houts AC (2012) Phase I trial of metronomic oral topotecan in combination with pazopanib utilizing a daily dosing schedule to treat recurrent or persistent gynaecologic tumors. J Clin Onc 30(suppl): Abstr 5014.
62. VassilakopouloüM, Mountzios G, Papamechael C, ProtogeroüAD, Aznaouridis K, Katsichti P, VenetsanoüK, Dimopoulos MA, Ikonomidis I, PapadimitrioüCA (2010) Paclitaxel chemotherapy and vascular toxicity as assessed by flow-mediated and nitrate-mediated vasodilatation. Vascul Pharmacol 53(3-4): 115-121.
63. Zweifel M, Jayson GC, Reed NS, Osborne R, Hassan B, Ledermann J, Shreeves G, Poupard L, LüSP, Balkissoon J, Chaplin DJ, Rustin GJ (2011) Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 22(9): 2036-2041.